Photo Credit: Mindaugas Kurmis
In a recent study, nicotinamide riboside was linked to improved walking function in patients with peripheral artery disease.
Nicotinamide riboside was associated with improved walking function in patients with peripheral artery disease (PAD) when compared with placebo, authors of a recent study discovered. This effect was not further enhanced by additional treatment with resveratrol. However, the authors concede these results require confirmation in larger trials.
The phase 2 NICE trial (NCT03743636) assessed the effect of nicotinamide riboside, a B3 vitamin and precursor to nicotinamide adenine dinucleotide (NAD+), on walking function in patients with PAD (n=90). Enrolled patients were randomized to nicotinamide riboside alone, 500 mg twice daily, to nicotinamide riboside plus resveratrol, 125 mg once daily, or to a placebo. The primary outcome was the change in 6-minute walking distance at 6 months. Mary McDermott, MD (Northwestern University), presented the study findings at AHA Scientific Sessions 2023.1
The 6-minute walking distance increased by 7.00 m in the monotherapy arm (P=0.078 vs placebo), decreased by 6.93 m in the combination therapy arm (P=0.376 vs placebo), and was reduced by 10.58 m in the placebo arm. However, in walk-adherent participants, both experimental arms were associated with improvements in walking distance compared with placebo:
- Monotherapy arm: mean difference +35.4 m (P=0.014).
- Combination therapy arm: mean difference +30.2 m (P=0.028).
In summary, in walking-adherent patients with PAD, the positive effects of the active arms on walking distance were comparable. “However, due to the limited sample size, there is a need to confirm these findings in larger clinical trials,” concluded Dr. McDermott.
Medical writing support was provided by Robert van den Heuvel.
Copyright ©2023 Medicom Medical Publishers
